Top Suppliers:I want be here
Related CAS#:
1417302-71-6 161748-29-4
99658-04-5 107444-51-9
1802078-26-7 1225021-13-5
215777-46-1 107444-07-5
94034-78-3 152617-91-9
920183-90-0 920373-01-9
920183-99-9 920413-74-7
920204-89-3 920413-90-7
920184-08-3 920204-98-4
920373-41-7 920373-57-5

1417302-71-6

1417302-71-6 structure
1417302-71-6 structure
  • Name: GLP-1(32-36)amide
  • Chemical Name: GLP-1(32-36)amide
  • CAS Number: 1417302-71-6
  • Molecular Formula: C25H50N10O5
  • Molecular Weight: 570.73
  • Catalog: Signaling Pathways GPCR/G Protein Glucagon Receptor
  • Create Date: 2021-09-12 19:20:08
  • Modify Date: 2024-01-13 15:38:15
  • GLP-1(32-36)amide, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice[1][2].
Name GLP-1(32-36)amide
Description GLP-1(32-36)amide, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice[1][2].
Related Catalog
In Vitro GLP-1(32-36)amide (0.1-10 μM; 24 h) retains cell viability and decreases apoptosis against Streptozotocin (STZ; 1 μM) in INS‐1 cells[2]. Cell Viability Assay[2] Cell Line: INS‐1 cells Concentration: 0.1, 1, 10 μM Incubation Time: 24 hours Result: Decreased cell viability only approximately 30% in 0.1 μM and approximately 20% in ≥1 μM while approximately 45% in saline-treated controls.
In Vivo GLP-1(32-36)amide (1 μmol/kg; i.p. once daily for 21 d) protects islet from damage, inhibits weight gain, and relieves symptoms of polydipsia in diabetic mice[2]. GLP-1(32-36)amide (1 μmol/kg; a single i.p.) slightly reduces the mean glucose lever at 30 min after the challenge of glucose in normal mice[2]. GLP-1(32-36)amide (50-70 nmol/kg/d; infusion for 12-16 weeks) prevents the development of diet-induced obesity and hepatic steatosis in high fat-fed mice[3]. Animal Model: Male KM mice (6-8 weeks; 18-22 g) injected with STZ[2] Dosage: 1 μmol/kg Administration: I.p. once daily for 21 days Result: Significantly lowered the cumulative values of food and water intake. Lowered fasting glucose. Reduced the level of Hemoglobin A1c (HbA1c). Improved glucose tolerance. Suppressed body weight gain.
References

[1]. Elahi D, et, al. GLP-1(32-36)amide, a novel pentapeptide cleavage product of GLP-1, modulates whole body glucose metabolism in dogs. Peptides. 2014 Sep;59:20-4.

[2]. Sun L, et, al. Novel Pentapeptide GLP-1 (32-36) Amide Inhibits β-Cell Apoptosis In Vitro and Improves Glucose Disposal in Streptozotocin-Induced Diabetic Mice. Chem Biol Drug Des. 2015 Dec;86(6):1482-90.

[3]. Tomas E, et, al. GLP-1(32-36)amide Pentapeptide Increases Basal Energy Expenditure and Inhibits Weight Gain in Obese Mice. Diabetes. 2015 Jul;64(7):2409-19.
Molecular Formula C25H50N10O5
Molecular Weight 570.73
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Chemsrc provides CAS#:1417302-71-6 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 1417302-71-6 | Chemsrc address: https://m.chemsrc.com/en/baike/1571593.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved